ELECTRONIC DEVICE FOR COLORIZING BLACK AND WHITE IMAGE USING GAN BASED MODEL COMPRISING TRANSFORMER BLOCK AND METHOD FOR OPERATION THEREOF

    公开(公告)号:US20240265587A1

    公开(公告)日:2024-08-08

    申请号:US18422534

    申请日:2024-01-25

    CPC classification number: G06T11/001

    Abstract: In accordance with various embodiments, an electronic device for colorizing a black and white image using a Generative Adversarial Network (GAN)-based model comprising a transformer block includes a processor, wherein the processor is set to: obtain a black and white image including only first information about a luminance channel; and generate a pseudo color image including only second information about a chrominance channel by applying the black and white image to the GAN-based model, the GAN-based model includes a generator network including a plurality of transformer blocks for color conversion, a plurality of convolution layers, and a plurality of transpose convolution layers, the plurality of transformer blocks each include a Depth Wise Convolution (DWC) layer, a first Layer Normalization (LN) layer, a Window-based Multi-head Self Attention (W-MSA) layer, a second LN layer, and a Colorization Feed Forward (CFF) block. Other various embodiments are possible.

    PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BRAIN AND NERVOUS SYSTEM DISEASES

    公开(公告)号:US20240238343A1

    公开(公告)日:2024-07-18

    申请号:US18004562

    申请日:2021-07-01

    Abstract: The present invention relates to a pharmaceutical composition comprising nasal inferior turbinate-derived mesenchymal stem cells as an active ingredient, the composition being administered by intranasal or intramaxillary administration by means of olfactory mucosa subepithelial injection, and the like, in order to bypass the blood-brain barrier through a peri-olfactory pathway. The present invention relates to a method in which stem cells, and the like are injected intranasally, thereby enabling various therapeutic materials including the stem cells to be efficiently delivered to the brain and nervous system through the olfactory organ and a trigeminal nervous system pathway, and thus, through the method, it was confirmed that side effects occurring as a result of an entire body being exposed to a drug may be reduced, and further, a sufficient amount of inferior turbinate-derived mesenchymal stem cells may be obtained safely at a desired time at low cost with high efficiency, and it was confirmed that since the composition shares the same genetic origin with the composition-administered subject, the composition exhibits an excellent effect which is the same as or greater than the effects of bone marrow-derived mesenchymal stem cells or adipose-derived mesenchymal stem cells with fewer side effects, and thus, by intranasally administering various therapeutic materials including the nasal inferior turbinate-derived mesenchymal stem cells, the composition is expected to be capable of minimizing side effects and utilized for preventing or developing a treatment for brain and nervous system diseases.

Patent Agency Ranking